Cibus stock plunges to 52-week low, hits $1.8 amid sharp decline

Cibus Global Ltd. shares have tumbled to a 52-week low, with the stock price touching down at $1.8, marking a significant downturn for the company. According to InvestingPro data, the stock’s elevated beta of 2.05 indicates higher volatility compared to the broader market, while a concerning current ratio of 0.85 suggests potential liquidity challenges. This latest price level reflects a stark contrast to the stock’s performance over the past year, with Cibus Global witnessing a precipitous 1-year change of -90.96%. Investors are closely monitoring the stock as it navigates through this challenging period, which has seen its value erode substantially from previous levels. The steep decline to this new 52-week low has raised concerns among shareholders about the underlying factors contributing to the company’s downward trajectory and the potential for recovery. InvestingPro analysis reveals concerning fundamentals, with an EBITDA of -$70.11M in the last twelve months and an overall Financial Health score rated as WEAK. For deeper insights, investors can access 12 additional ProTips and a comprehensive Pro Research Report covering this and 1,400+ other US stocks.

In other recent news, Cibus Inc. reported its Q4 2024 earnings, revealing a net loss of $25.8 million, a substantial improvement from the previous year’s $277.2 million loss. This improvement is attributed to strategic realignment and cost-saving measures, including reductions in R&D and personnel costs. The company has $14.4 million in cash and cash equivalents as of December 31, 2024, and has also received $21.6 million from a registered direct offering in January 2025. Cibus is advancing its gene editing technology across key crops like rice, canola, and soybean, with plans to generate initial bio-fragrance revenues by 2026. The company anticipates receiving the first royalties from canola and winter oilseed rape between 2026 and 2028. Recent developments also include Cibus’s collaboration with Biographica to enhance its disease resistance program using AI. Analysts from firms like Jefferies and Canaccord have shown interest in Cibus’s progress, particularly regarding regulatory advancements in Europe that may impact the company’s market strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.